Ralliant (NYSE:RAL) Raised to Strong-Buy at Wall Street Zen

Posted by on Aug 5th, 2026

Ralliant (NYSE:RAL – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday.

Other analysts have also issued research reports about the stock. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. BMO Capital Markets started coverage on shares of Ralliant in a research report on Monday, July 20th. They set a “market perform” rating and a $78.00 price target on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, Vertical Research cut Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ralliant presently has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Read Our Latest Analysis on Ralliant

Ralliant Stock Up 3.0%

Shares of Ralliant stock opened at $67.13 on Monday. The firm has a market cap of $7.43 billion, a PE ratio of -6.19, a P/E/G ratio of 2.42 and a beta of 1.60. The business’s 50 day simple moving average is $67.37 and its 200 day simple moving average is $54.54. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. Ralliant has a 52-week low of $37.27 and a 52-week high of $75.41.

Ralliant (NYSE:RAL – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, analysts predict that Ralliant will post 2.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ralliant

Institutional investors have recently bought and sold shares of the business. Viking Global Investors LP bought a new stake in Ralliant in the second quarter valued at approximately $257,200,000. State Street Corp bought a new position in shares of Ralliant during the 2nd quarter worth approximately $213,096,000. Millennium Management LLC increased its holdings in shares of Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock worth $253,175,000 after acquiring an additional 3,147,660 shares during the last quarter. Norges Bank acquired a new position in shares of Ralliant during the 4th quarter worth approximately $124,687,000. Finally, Invesco Ltd. raised its stake in Ralliant by 90.1% in the 3rd quarter. Invesco Ltd. now owns 3,871,690 shares of the company’s stock valued at $169,309,000 after acquiring an additional 1,835,128 shares during the period.

Ralliant Company Profile

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Featured Articles

Analyst Recommendations for Ralliant (NYSE:RAL)

Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.